New Glaucoma Treatment Could Better Lower Eye Pressure
Omaha researchers are developing a new compound that may offer more effective, long-lasting relief for glaucoma patients.
Updated on Oct. 28, 2026 in Asthma
Live Poll
Should government agencies prioritize funding for the development of new pharmaceutical treatments?
Creighton University researchers received a $2.9 million grant from the National Institutes of Health to develop a new glaucoma treatment. The project focuses on a compound designed to lower eye pressure more effectively than current medications.
Why it matters
Existing glaucoma treatments reduce eye pressure but often fail to prevent damage to retinal nerve cells, potentially leading to blindness. This new research aims to provide a more effective alternative that addresses these underlying risks.
In early preclinical animal studies, the experimental compound achieved a 54% reduction in eye pressure compared to the 33% typically seen with existing medications. These preliminary findings are based on a test cohort, and researchers are still investigating over 100 variations of the treatment.
The players
National Institutes of Health
The primary federal agency responsible for biomedical and public health research in the United States.
Creighton University
A private Jesuit university in Omaha where the research team is based.
The details
The research team is developing a compound that combines latanoprost with nitric oxide and hydrogen sulfide to target elevated intraocular pressure. By integrating these three agents, the compound aims to sustain its effects for 52 hours. Researchers are currently iterating through more than 100 versions of the formula to optimize its therapeutic impact before proceeding to human trials.
Timeline
Grant funds will be distributed over the next 5 years.
Health Landscape
This project represents a targeted effort to improve upon standard glaucoma management by developing treatments that offer longer-lasting pressure relief. It aligns with the National Institutes of Health glaucoma research initiative to innovate beyond current pharmacological limits.
This research is in the early animal-testing phase and is not yet available for clinical use. Patients currently managing glaucoma should continue their prescribed regimens and discuss any questions about treatment goals with their ophthalmologist.
The takeaway
While this experimental compound demonstrates potential for superior pressure reduction in animal models, it remains several years from market availability. For now, prioritize regular screenings and follow your physician's guidance regarding current glaucoma management strategies.
Further reading
Learn more about the latest developments in respiratory and ocular health on our Asthma page.
Source note: This article includes information reported by Star-Herald.
Live Poll
Should government agencies prioritize funding for the development of new pharmaceutical treatments?
